Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) FCF Margin (2022 - 2025)

Bioregenx has reported FCF Margin over the past 4 years, most recently at 17.26% for Q4 2025.

  • For Q4 2025, FCF Margin rose 1973.0% year-over-year to 17.26%; the TTM value through Dec 2025 reached 1.61%, up 2356.0%, while the annual FY2025 figure was 1.61%, 2356.0% up from the prior year.
  • FCF Margin for Q4 2025 was 17.26% at Bioregenx, up from 15.28% in the prior quarter.
  • Over five years, FCF Margin peaked at 17.26% in Q4 2025 and troughed at 271.55% in Q1 2022.
  • A 4-year average of 53.76% and a median of 33.49% in 2023 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: soared 24023bps in 2023 and later crashed -2212bps in 2024.
  • Year by year, FCF Margin stood at 48.96% in 2022, then rose by 26bps to 36.23% in 2023, then soared by 93bps to 2.47% in 2024, then soared by 800bps to 17.26% in 2025.
  • Business Quant data shows FCF Margin for BRGX at 17.26% in Q4 2025, 15.28% in Q3 2025, and 0.72% in Q2 2025.